TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34931667

Group type: EXPERIMENTAL
Intervention: 60 µg RSVpreF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 120 µg RSVpreF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 240 µg RSVpreF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RSVpreF with SIIV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34508805

Group type: EXPERIMENTAL
Intervention: Behavior therapy responders (n = 21)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Psychoeducation/supportive therapy responders (n = 6)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 80
Study: 33892670

Group type: EXPERIMENTAL
Intervention: PDLASTA® (Pegfilgrastim) - single subcutaneous dose
Number of subjects: 80

Group type: COMPARATOR
Intervention: PDGRASTIM® (Filgrastim) - repeated six daily injections
Number of subjects: 80
Study: 36293977

Group type: EXPERIMENTAL
Intervention: Indoor climbing (IG), 2 times per week for 10 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indoor climbing (IG) for females
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sports programme (CGI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (CGII)
Number of subjects: 0
Study: 33833090

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) - three individual sessions
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no MI)
Number of subjects: 40
Study: 34811374

Group type: EXPERIMENTAL
Intervention: Running at moderate intensity (10-min session on a treadmill at 50%)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (resting session)
Number of subjects: 26
Study: 32720550

Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Neutrally Adjusted Ventilatory Assist (NAVA)
Number of subjects: 15
Study: 35055694

Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 20% glucose administered orally
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Non-nutritive sucking
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Heart rate variability
Number of subjects: 90
Study: 33482045

Group type: EXPERIMENTAL
Intervention: Grounded flaxseed (GF) 30 gr/day
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Flaxseed oil (FO) 10 gr/day
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 32873290

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg/day for 3 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 35265174

Group type: EXPERIMENTAL
Intervention: Ultrasonic detection based on the random forest segmentation algorithm
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional ultrasonic detection
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tear osmotic pressure
Number of subjects: 100
Study: 33795567

Group type: EXPERIMENTAL
Intervention: Pulse-dye laser followed by fractional ablative CO2 laser-assisted delivery of betamethasone-calcipotriol gel
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (untreated hand)
Number of subjects: 22
Study: 33299395

Group type: EXPERIMENTAL
Intervention: Integrative Body‐Mind Training (IBMT), 10 hours of mindfulness training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active control - relaxation training (RT)
Number of subjects: 0
Study: 35215521

Group type: EXPERIMENTAL
Intervention: Dietary intervention (one serving of supplementary food, Nestle Sinlac, for 3 months)
Number of subjects: 38
Study: 33847325

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks for 24 weeks
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks for 52 weeks
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 624

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 624
Study: 32318744

Group type: EXPERIMENTAL
Intervention: Crisaborole ointment, 2%, applied twice daily for 28 days
Number of subjects: 1522

Group type: COMPARATOR
Intervention: Vehicle, applied twice daily for 28 days
Number of subjects: 1522
Study: 36317518

Group type: EXPERIMENTAL
Intervention: Tegoprazan (50, 100, or 200 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Dexlansoprazole (60 mg)
Number of subjects: 24
Study: 33835026

Group type: EXPERIMENTAL
Intervention: Onsite urban sanitation intervention (pour-flush toilets with septic tanks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm (comparable group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Children born into study sites after intervention
Number of subjects: 0
Study: 32247714

Group type: EXPERIMENTAL
Intervention: Intermittent enteral feeding (six 4-hourly feeds per 24 h, n = 62)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Intermittent enteral feeding
Number of subjects: 121

Group type: COMPARATOR
Intervention: Continuous enteral feeding (n = 59)
Number of subjects: 121
Study: 35428631

Group type: EXPERIMENTAL
Intervention: Immediate delivery based on cerebral blood flow redistribution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed delivery based on cCTG abnormalities or other worsening fetal condition
Number of subjects: 0
Study: 34128862

Group type: EXPERIMENTAL
Intervention: Supraglottic airway (SGA) devices
Number of subjects: 66

Group type: COMPARATOR
Intervention: Endotracheal tube (ETT) devices
Number of subjects: 66
Study: 35191923

Group type: EXPERIMENTAL
Intervention: Invasive strategy group (n=124): mechanical compression, intra-arrest transport to a cardiac center for ECPR and immediate invasive assessment and treatment.
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Invasive strategy group (n=124)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Standard strategy group (n=132)
Number of subjects: 256
Study: 34021031

Group type: EXPERIMENTAL
Intervention: Nephrologist follow-up
Number of subjects: 71

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 71
Study: 33453008

Group type: EXPERIMENTAL
Intervention: Underbody forced air warming blanket
Number of subjects: 60

Group type: COMPARATOR
Intervention: Over-body forced air warming blanket
Number of subjects: 60
Study: 33155090

Group type: EXPERIMENTAL
Intervention: Medial Pivot (MP) TKA
Number of subjects: 53

Group type: COMPARATOR
Intervention: Posterior Stabilized (PS) TKA
Number of subjects: 53
Study: 35080078

Group type: EXPERIMENTAL
Intervention: Lemon Essential Oil (LEO)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Cetylpyridinium Chloride (CPC)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Chlorhexidine (CHX)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Hydrogen Peroxide (H2O2)
Number of subjects: 48
Study: 32338293

Group type: EXPERIMENTAL
Intervention: Dermoscopy
Number of subjects: 136
Study: 35312652

Group type: EXPERIMENTAL
Intervention: Patient navigation intervention (single session and biweekly check-ins)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 60
Study: 35151514

Group type: EXPERIMENTAL
Intervention: Visual Abstracts (VAs)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Key Figures (KFs)
Number of subjects: 200
Study: 35760493

Group type: EXPERIMENTAL
Intervention: Enterosgel (polymethylsiloxane polyhydrate)
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Open-label treatment with Enterosgel
Number of subjects: 440

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 440
Study: 34145803

Group type: COMPARATOR
Intervention: Nerve blockade (n=50)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA) (n=52)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control group (n=59)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: LIA (n=52)
Number of subjects: 161
Study: 36562843

Group type: EXPERIMENTAL
Intervention: TII collagen
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Glucosamine hydrochloride + chondroitin sulfate (G + C)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 33150187

Group type: EXPERIMENTAL
Intervention: Melatonin (M)
Number of subjects: 5

Group type: COMPARATOR
Intervention: 24 h light (24HL)
Number of subjects: 5

Group type: COMPARATOR
Intervention: 12 h light (12HL)
Number of subjects: 5

Group type: COMPARATOR
Intervention: High-fat diet (HFD)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 5
Study: 33300323

Group type: EXPERIMENTAL
Intervention: Pupillometry-guided remifentanil administration
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional remifentanil administration
Number of subjects: 54
Study: 32992062

Group type: EXPERIMENTAL
Intervention: Ultrasound imaging of the sciatic nerve and its branches using PHILIPSiU22 colour Doppler ultrasound with L12-5 high-frequency probe.
Number of subjects: 0
Study: 35904728

Group type: EXPERIMENTAL
Intervention: Paper survey
Number of subjects: 244

Group type: COMPARATOR
Intervention: Telephone automated computer assisted structured interview (TACASI)
Number of subjects: 244
Study: 33277980

Group type: EXPERIMENTAL
Intervention: Fosaprepitant dimeglumine (FD) intravenously administered (test group)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Reference product (FD) intravenously administered (reference group)
Number of subjects: 29
Study: 35438649

Group type: EXPERIMENTAL
Intervention: 686 Program plus Lay health supporters, e‐platform, award, and integration (LEAN)
Number of subjects: 277

Group type: COMPARATOR
Intervention: 686 Program
Number of subjects: 277
Study: 33769603

Group type: EXPERIMENTAL
Intervention: Nurse-led personalized telephone lifestyle intervention
Number of subjects: 428

Group type: COMPARATOR
Intervention: Automated SMSs
Number of subjects: 428
Study: 34826572

Group type: EXPERIMENTAL
Intervention: TENS (n=108)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo TENS (n=112)
Number of subjects: 220
Study: 33321447

Group type: EXPERIMENTAL
Intervention: Chromium supplementation
Number of subjects: 0
Study: 35578409

Group type: EXPERIMENTAL
Intervention: Virtual simulation of code white
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study: 35272485

Group type: EXPERIMENTAL
Intervention: encorafenib + binimetinib + pembrolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: pembrolizumab
Number of subjects: 0
Study: 34060861

Group type: EXPERIMENTAL
Intervention: Perspective-taking condition (n = 45)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Objective condition (n = 46)
Number of subjects: 91
Study: 33105016

Group type: EXPERIMENTAL
Intervention: Ustekinumab, a monoclonal antibody targeting IL-12/23
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mirikizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risankizumab
Number of subjects: 0
Study: 35950949

Group type: EXPERIMENTAL
Intervention: Three-monthly viral load (VL) testing with additional drug exposure and drug resistance testing in case of viral rebound.
Number of subjects: 501

Group type: COMPARATOR
Intervention: Standard-of-care monitoring according to WHO-guidelines (annual VL testing).
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Three-monthly VL testing.
Number of subjects: 501

Group type: COMPARATOR
Intervention: Standard-of-care monitoring (annual VL testing).
Number of subjects: 501
Study: 34794285

Group type: EXPERIMENTAL
Intervention: S-adenosyl-L-methionine (SAMe) plus UDCA
Number of subjects: 102

Group type: COMPARATOR
Intervention: UDCA
Number of subjects: 102
Study: 32438493

Group type: EXPERIMENTAL
Intervention: LASSO-model incorporating fetal NT and eight ultrasonographic facial markers
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: LASSO-model in retest set
Number of subjects: 624

Group type: COMPARATOR
Intervention: LASSO-model compared to model based on fetal NT and maternal age
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: Nomogram of LASSO-model
Number of subjects: 624
Study: 33092424

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 172

Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: R value, K value, α angle, and MA at 3 days after surgery
Number of subjects: 172
Study: 35867153

Group type: EXPERIMENTAL
Intervention: NightLase
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 40
Study: 33541338

Group type: EXPERIMENTAL
Intervention: Early intervention program based on enhanced maternal care and positive multisensory stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 32773816

Group type: EXPERIMENTAL
Intervention: FSD denture (CAD/CAM)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional denture
Number of subjects: 20
Study: 35943798

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice a day
Number of subjects: 15

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 15
Study: 34115682

Group type: EXPERIMENTAL
Intervention: ATX-101 0.5%
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: ATX-101 1.0%
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: ATX-101 2.0%
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 35244287

Group type: EXPERIMENTAL
Intervention: Low dose rFSH (0.5 IU/kg/d)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Medium dose rFSH (1.1 IU/kg/d)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High dose rFSH (2.2 IU/kg/d)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (ovulatory controls)
Number of subjects: 30
Study: 36507215

Group type: EXPERIMENTAL
Intervention: Riluzole administration (group A)
Number of subjects: 43

Group type: COMPARATOR
Intervention: No adjuvants (group B)
Number of subjects: 43
Study: 33616598

Group type: EXPERIMENTAL
Intervention: Time-Restricted Eating (TRE)
Number of subjects: 0
Study: 32961353

Group type: EXPERIMENTAL
Intervention: Body 50 (n=19)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Tip 50 (n=29)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Body 400 (n=24)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Tip 400 (n=21)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control (n=16)
Number of subjects: 93
Study: 35788868

Group type: EXPERIMENTAL
Intervention: Self-directed program with supplemental support (n=110)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Treatment as usual control condition (n=110)
Number of subjects: 220
Study: 33637048

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL) treatment
Number of subjects: 0
Study: 35943883

Group type: EXPERIMENTAL
Intervention: Riboflavin 50 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Riboflavin 100 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined Riboflavin 50 and 100 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33580297

Group type: EXPERIMENTAL
Intervention: β‐d‐glucan‐enriched mixture (10.4 g/day) from Lentinula edodes
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo incorporated in three different commercial creams
Number of subjects: 52
Study: 32819461

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1800
Study: 35109864

Group type: EXPERIMENTAL
Intervention: Radiomics signature (containing four PET/CT features and four clinical factors)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Radiomics signature for stage III patients (containing two clinical features and two radiomics features)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: K-M curves of both models
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Selected radiomics features
Number of subjects: 196
Study: 32920843

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 90

Group type: COMPARATOR
Intervention: Clomiphene Citrate (CC)
Number of subjects: 90
Study: 32555624

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (2 sessions/week)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (6 sessions/week)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Sedentary control
Number of subjects: 52
Study: 35507468

Group type: EXPERIMENTAL
Intervention: Arthroscopic suprapectoral biceps tenodesis (ASPBT)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Open subpectoral biceps tenodesis (OSPBT)
Number of subjects: 73
Study: 34244154

Group type: COMPARATOR
Intervention: Phone counseling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Web-based intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Web + Phone counseling
Number of subjects: 0
Study: 32358874

Group type: EXPERIMENTAL
Intervention: ARMEO ULE
Number of subjects: 45

Group type: COMPARATOR
Intervention: Therapist‐assisted Table Top (TAT)
Number of subjects: 45
Study: 32205274

Group type: EXPERIMENTAL
Intervention: Real Energy Regulation Group (TG)
Number of subjects: 22
Study: 35997978

Group type: EXPERIMENTAL
Intervention: Edoxaban (15 mg daily)
Number of subjects: 984

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 984
Study: 33108910

Group type: EXPERIMENTAL
Intervention: Planning + text message intervention (n=29)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (n=31)
Number of subjects: 60
Study: 32341707

Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Aromatherapy with chamomile-lavender essential oil
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both music therapy and aromatherapy with chamomile-lavender essential oil
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study: 35821512

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT), 40 sessions daily
Number of subjects: 73
Study: 33021146

Group type: EXPERIMENTAL
Intervention: Application to track daily walking steps and interact via text messages with group members for 4 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Application only to track own walking steps
Number of subjects: 60
Study: 32822286

Group type: EXPERIMENTAL
Intervention: Binimetinib (45 mg twice daily)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Physician's choice chemotherapy (PCC)
Number of subjects: 303
Study: 36384181

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) in seven weekly sessions for eight weeks
Number of subjects: 36
Study: 33693724

Group type: COMPARATOR
Intervention: Glycemic Load (GL) - highest quartile
Number of subjects: 66643

Group type: COMPARATOR
Intervention: Glycemic Index (GI) - highest quartile
Number of subjects: 66643
Study: 32854231

Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment for 3 months
Number of subjects: 33

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 33
Study: 34064493

Group type: EXPERIMENTAL
Intervention: Prednisone and antibiotherapy with surgical periodontal therapy
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ketoprofen and antibiotherapy with surgical periodontal therapy
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Prednisone alone
Number of subjects: 22

Group type: COMPARATOR
Intervention: Routine scaling and polishing (Control group)
Number of subjects: 22
Study: 33885041

Group type: EXPERIMENTAL
Intervention: Pharmacologic prophylaxis (low molecular weight heparin)
Number of subjects: 180932

Group type: COMPARATOR
Intervention: Pharmacologic prophylaxis (unfractionated heparin)
Number of subjects: 180932

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 180932
Study: 34259402

Group type: EXPERIMENTAL
Intervention: Intradermal needling combined with heat-sensitive moxibustion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Opioids according to the three-step analgesic method of WHO
Number of subjects: 60
Study: 33169138

Group type: EXPERIMENTAL
Intervention: NORTH STAR
Number of subjects: 24

Group type: COMPARATOR
Intervention: Assessment-and-feedback-only condition (Control)
Number of subjects: 24
Study: 32299860

Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI
Number of subjects: 10355

Group type: COMPARATOR
Intervention: FF/VI
Number of subjects: 10355

Group type: COMPARATOR
Intervention: UMEC/VI
Number of subjects: 10355
Study: 33713397

Group type: EXPERIMENTAL
Intervention: Tripterygium glycosides
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 33103600

Group type: EXPERIMENTAL
Intervention: Two-sided refutational messages
Number of subjects: 609

Group type: COMPARATOR
Intervention: Conspiracy framed misinformation messages
Number of subjects: 609

Group type: COMPARATOR
Intervention: Uncertainty framed misinformation messages
Number of subjects: 609
Study: 36442435

Group type: COMPARATOR
Intervention: Basic health information presentation 1 (control group)
Number of subjects: 1066

Group type: COMPARATOR
Intervention: Basic health information presentation 2 (control group)
Number of subjects: 1066
Study: 34369941

Group type: EXPERIMENTAL
Intervention: IANB plus buccal infiltration (1.8 mL IANB + 1.8 mL buccal infiltration)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: IANB (3.6 mL)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: IANB plus lingual infiltration (1.8 mL IANB + 1.8 mL lingual infiltration)
Number of subjects: 60

Group type: COMPARATOR
Intervention: IANB
Number of subjects: 60

Group type: COMPARATOR
Intervention: IANB plus lingual infiltration
Number of subjects: 60

Group type: COMPARATOR
Intervention: IANB plus buccal infiltration
Number of subjects: 60
Study: 33687747

Group type: EXPERIMENTAL
Intervention: Molecularly guided therapy
Number of subjects: 628

Group type: COMPARATOR
Intervention: Platinum-based chemotherapy
Number of subjects: 628
Study: 32033532

Group type: EXPERIMENTAL
Intervention: Tailored strengthening and balance exercises
Number of subjects: 190

Group type: COMPARATOR
Intervention: Stretching and relaxation exercises (Control)
Number of subjects: 190
Study: 33065952

Group type: EXPERIMENTAL
Intervention: 40U daxibotulinumtoxinA
Number of subjects: 191

Group type: COMPARATOR
Intervention: 20U onabotulinumtoxinA
Number of subjects: 191

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191

Group type: COMPARATOR
Intervention: 20U daxibotulinumtoxinA
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: 60U daxibotulinumtoxinA
Number of subjects: 191